Welcome to our dedicated page for Axogen news (Ticker: AXGN), a resource for investors and traders seeking the latest updates and insights on Axogen stock.
Axogen, Inc. develops and commercializes surgical solutions for peripheral nerve regeneration and repair. The company’s recurring updates center on its portfolio for restoration of peripheral nerve function, including Avance® (acellular nerve allograft-arwx), Avance® Nerve Graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, and Avive+ Soft Tissue Matrix™.
Company news also includes quarterly and annual financial results, revenue guidance, gross margin and cash metrics, investor-conference participation, FDA-related developments for Avance, and capital-structure actions involving common stock. These updates connect operating performance with Axogen’s commercial activity in nerve repair products across its target markets.
Axogen, Inc. (NASDAQ: AXGN) announced it will release its fourth quarter and full-year 2020 financial results on February 22, 2021, after market close. An investment-community conference call will follow at 4:30 p.m. ET, where management will discuss the results. Participation is available via phone or live webcast on the company’s website. Axogen specializes in surgical solutions for peripheral nerve damage, offering products like Avance® Nerve Graft and Axoguard® product line. The company aims to enhance patient recovery and quality of life through innovative nerve repair technologies.
Axogen (AXGN) reported preliminary fourth quarter 2020 revenue of at least $32.4 million, a 15% increase from Q4 2019's $28.2 million. Full-year revenue is projected to be at least $112.2 million, a 5% increase compared to $106.7 million in 2019. The company enhanced its sales team, growing to 111 direct sales representatives and increased active accounts by 12% to 893. Axogen surpassed 50,000 Avance® Nerve Grafts implanted, demonstrating commitment to restoring nerve function despite the pandemic's challenges.
Axogen (NASDAQ: AXGN), a leader in nerve repair solutions, will present clinical evidence at the 2021 American Association for Hand Surgery, American Society for Peripheral Nerve, and American Society for Reconstructive Microsurgery meetings held virtually from January 10-17. The company will host a symposium on January 17 featuring experts discussing significant 2020 publications in nerve reconstruction. Axogen's research will be highlighted in various sessions, addressing topics like nerve conduits and recovery outcomes following surgical interventions.
Axogen (NASDAQ: AXGN) announces its sponsorship of Donate Life at the Tournament of Roses celebration, emphasizing the importance of organ and tissue donation during the pandemic. The 2021 Rose Parade will honor 21 donors and six transplant professionals, including nerve repair surgeons. CEO Karen Zaderej highlights that restoring nerve function relies on tissue donations. Axogen continues to support donation initiatives year-round, illustrating its commitment to enhancing patient quality of life through innovative surgical solutions.
Axogen, Inc. (NASDAQ: AXGN) announced that its chairman and CEO, Karen Zaderej, will present at two investor events in November 2020. The first event, the Jefferies Virtual London Healthcare Conference, is scheduled for November 18 at 3:15 p.m. (10:15 a.m. ET). The second, the Canaccord Genuity Virtual MedTech & Diagnostics Forum, will take place on November 19 at 10:00 a.m. ET. Both presentations will be available via live webcast on the company's Investors page and will be archived for 90 days.
Axogen reported a 17% increase in net revenue for Q3 2020, reaching $33.4 million, up from $28.6 million in Q3 2019. The gross margin stood at 83.0%, slightly down from 84.2% a year prior. Notably, the company narrowed its net loss to $1.5 million or $0.04 per share, significantly improving from a loss of $5.6 million or $0.14 per share year-over-year. Adjusted EBITDA was $2.3 million, a recovery from the prior year's loss. Operationally, active accounts grew by 11% to 875.
Axogen, Inc. (NASDAQ: AXGN) announced that it will report its third quarter 2020 financial results on October 29, 2020, after market close. An investment-community conference call and webcast will follow at 4:30 p.m. ET. Interested investors can join the call by phone or via a webcast on Axogen's website. The company focuses on developing innovative surgical solutions for peripheral nerve damage, offering products like Avance® Nerve Graft and Axoguard® series.
Axogen, Inc. (NASDAQ: AXGN) appointed healthcare veteran Paul G. Thomas to its Board of Directors effective September 30, 2020. With over 30 years of medtech experience, Thomas will enhance Axogen's strategic direction, serving on the Governance, Nominating and Sustainability Committee and the Science and Technology Committee. He previously held leadership roles at Abiomed and LifeCell Corporation. Thomas succeeds Robert J. Rudelius, who resigned after a decade of service. The company focuses on innovative surgical solutions for peripheral nerve repair, emphasizing improved quality of life for patients.
Axogen, a leader in surgical solutions for peripheral nerve damage, announced that CEO Karen Zaderej will present at the JMP Securities MedTech Bio Summit on October 1, 2020, at 11:00 a.m. ET. This virtual event will be accessible via Axogen's Investors page, with a replay available for 90 days. Axogen focuses on technologies for nerve regeneration and has a comprehensive product portfolio, including Avance® Nerve Graft and Axoguard® series, aimed at restoring nerve function and improving patient outcomes.
Axogen (NASDAQ: AXGN) will participate in the 75th Annual Meeting of the American Society for Surgery of the Hand from October 1-3, 2020. Key presentations will highlight the clinical and economic benefits of Avance Nerve Graft compared to traditional nerve autografts. Clinical data from the RANGER® Registry shows comparable outcomes for sensory and motor nerve injuries. Additionally, a cost evaluation confirms Avance's procedural costs are competitive. Axogen will also host a virtual symposium, Nerve Repair Live, on September 29, featuring live surgical demonstrations.